DorisTanMIL
2021-09-01
Pls like
Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":816649705,"tweetId":"816649705","gmtCreate":1630500160707,"gmtModify":1632476260683,"author":{"id":3582942873418844,"idStr":"3582942873418844","authorId":3582942873418844,"authorIdStr":"3582942873418844","name":"DorisTanMIL","avatar":"https://static.tigerbbs.com/75b9822f6cf594977f9894a9b2c5a4cf","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Pls like</p></body></html>","htmlText":"<html><head></head><body><p>Pls like</p></body></html>","text":"Pls like","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/816649705","repostId":1128019873,"repostType":4,"repost":{"id":"1128019873","kind":"news","pubTimestamp":1630499831,"share":"https://www.laohu8.com/m/news/1128019873?lang=&edition=full","pubTime":"2021-09-01 20:37","market":"us","language":"en","title":"Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1128019873","media":"Benzinga","summary":"The FDA has accepted Teva Pharmaceutical Industries Ltd and MedinCell's marketing application seeki","content":"<ul>\n <li>The FDA has accepted <b>Teva Pharmaceutical Industries Ltd</b> and <b>MedinCell's</b> marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia.</li>\n <li>TV-46000/mdc-IRM is a risperidone extended-release injectable suspension for subcutaneous use.</li>\n <li>The acceptance is based on Phase 3 data from two pivotal studies. Results will be shared at future scientific conferences and in peer-reviewed publications.</li>\n <li>Teva will continue to lead the clinical development and regulatory process and be responsible for the commercialization of this candidate treatment, with MedinCell eligible for development milestones, royalties on net sales, and future commercial milestones.</li>\n <li>Teva is also conducting another Phase 3 study designed to evaluate the long-term safety, tolerability, and effectiveness of TV-46000 subcutaneously administered for up to 56 weeks in 331 schizophrenia patients.</li>\n <li>The primary endpoint is the frequency of all adverse events, including serious adverse events. This study is ongoing; interim results align with the findings of the RISE study.</li>\n <li><b>Price Action:</b> TEVA shares are up 0.64% at $9.48 during the premarket session on the last check Wednesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva-MedinCell's Schizophrenia Treatment Candidate Under FDA Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-01 20:37 GMT+8 <a href=https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The FDA has accepted Teva Pharmaceutical Industries Ltd and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia.\nTV-46000/mdc-IRM is a risperidone extended-...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TEVA":"梯瓦制药"},"source_url":"https://www.benzinga.com/general/biotech/21/09/22755095/teva-medincells-schizophrenia-treatment-candidate-under-fda-review","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128019873","content_text":"The FDA has accepted Teva Pharmaceutical Industries Ltd and MedinCell's marketing application seeking approval for TV-46000/mdc-IRM in schizophrenia.\nTV-46000/mdc-IRM is a risperidone extended-release injectable suspension for subcutaneous use.\nThe acceptance is based on Phase 3 data from two pivotal studies. Results will be shared at future scientific conferences and in peer-reviewed publications.\nTeva will continue to lead the clinical development and regulatory process and be responsible for the commercialization of this candidate treatment, with MedinCell eligible for development milestones, royalties on net sales, and future commercial milestones.\nTeva is also conducting another Phase 3 study designed to evaluate the long-term safety, tolerability, and effectiveness of TV-46000 subcutaneously administered for up to 56 weeks in 331 schizophrenia patients.\nThe primary endpoint is the frequency of all adverse events, including serious adverse events. This study is ongoing; interim results align with the findings of the RISE study.\nPrice Action: TEVA shares are up 0.64% at $9.48 during the premarket session on the last check Wednesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":131,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/816649705"}
精彩评论